Find Academic Supervisors

Jonathan KeatsView profile

Assistant Professor

• Multiple Myeloma
• Cancer Genomics
• Bioinformatics
• +4 more

Jonathan Keats, Ph.D., serves as an Assistant Professor at the Translational Genomics Research Institute (TGen) and holds the position of Scientific Director at the Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope. Additionally, he directs TGen's Bioinformatics division and the Collaborative Sequencing Center, which provides advanced genomic sequencing services to researchers worldwide. His work bridges cutting-edge genomics with clinical applications in cancer. Dr. Keats' educational journey includes: Ph.D. from the University of Alberta (2005), where he investigated the clinical and biological consequences of the t(4;14)(p16;q32) translocation in multiple myeloma under Dr. Linda Pilarski. Postdoctoral training at the Mayo Clinic with Dr. Leif Bergsagel, focusing on identifying novel genetic events in multiple myeloma pathogenesis. His research is predominantly centered on multiple myeloma, with secondary interests in other hematological malignancies and immunodeficiency syndromes. Dr. Keats employs innovative genomic and bioinformatic methodologies to dissect the molecular underpinnings of these diseases, particularly targeting pathways like NF-kB that drive tumor development, progression, and therapeutic resistance. His work aims to translate genomic discoveries into immediate clinical impact, aligning with TGen's ethos of 'helping someone today.' Analysis of Dr. Keats' publication record reveals a trajectory from early investigations of specific cytogenetic abnormalities (e.g., t(4;14)) to comprehensive genomic analyses. His landmark studies include the identification of NF-kB pathway mutations and participation in the Multiple Myeloma Genomics Initiative. Recent work leverages advanced sequencing technologies to uncover structural variants and epigenetic modifications, demonstrating a consistent focus on integrating multi-omics data to refine disease subtyping and identify therapeutic vulnerabilities in myeloma. Dr. Keats leads the Collaborative Sequencing Center at TGen, which utilizes state-of-the-art short-read, long-read (Oxford PromethION), and intermediate-read sequencers to provide gapless human genome assemblies. His laboratory at the Briskin Center conducts research on multiple myeloma genomics and is the lead site for the CoMMpass study, which has identified distinct myeloma subtypes based on genomic profiles. This work directly informs precision medicine approaches for myeloma patients.

Daylon JamesView profile

Assistant Professor

• Stem Cell Biology
• Regenerative Medicine
• Reproductive Endocrinology
• +2 more

Daylon James is an Assistant Professor in Stem Cell Biology at Weill Cornell Medicine , where he serves as Director of the Reproductive Endocrinology Laboratory and Manager of the Tri-Institutional Stem Cell Derivation Laboratory . His research program focuses on regenerative medicine and cell-based therapies for infertility , leveraging expertise in stem cell biology and xenograft models. PhD: The Rockefeller University Postdoctoral Training: Weill Cornell Medical College Research interests include: Stem cell differentiation for vascular and ovarian tissue regeneration Modified RNA delivery systems for fertility preservation Xenograft models in reproductive endocrinology Lipid metabolism in pluripotent stem cells Angiogenic and paracrine mechanisms for graft survival His publications reveal a focus on ovarian reserve disorders , anti-Müllerian hormone (AMH) applications , and endothelial cell engineering , with recent work exploring JAK inhibition for chemotherapy protection and cytoskeletal regulation in oocyte maturation. Labs and teams: Reproductive Endocrinology Laboratory Tri-Institutional Stem Cell Derivation Laboratory

Carman Man-chung LiView profile

Assistant Professor

• Cancer Biology
• Genetics
• Molecular Biology
• +3 more

Carman Man-chung Li is an Assistant Professor of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania. He is also an Assistant Investigator at the Abramson Family Cancer Research Institute and a Core Investigator at The Basser Center for BRCA. His research focuses on hereditary cancer mechanisms, particularly how heterozygous loss-of-function mutations in tumor suppressor genes drive early tumorigenesis beyond the classical 'two-hit' hypothesis. Education: A.B. in Molecular Biology (High Honors), Princeton University (2009); Ph.D. in Biology, Massachusetts Institute of Technology (2015) Using genetically engineered mouse models, organoid cultures, and multi-omics, his lab investigates gene haploinsufficiency effects, epigenetic alterations, and stromal-epithelial interactions. Recent work includes mapping early tumor drivers in BRCA1-mutant models and cross-ancestry cancer risk stratification. Scientific Affiliations: Abramson Family Cancer Research Institute The Basser Center for BRCA Graduate Groups: Pharmacology, Cell and Molecular Biology His lab collaborates with the Penn Medicine Biobank, VA Million Veterans Program, and EDISYN Consortium for translational studies in Li-Fraumeni Syndrome and BRCA-related cancers. Funding sources include the National Cancer Institute, Prostate Cancer Foundation, and Li Fraumeni Syndrome Association.

Dennis LoView profile

Professor

• Molecular Biology
• Non-invasive Prenatal Testing
• Liquid Biopsy
• +3 more

Professor Dennis Lo is a renowned Hong Kong molecular biologist and the Vice-Chancellor and President of the Chinese University of Hong Kong (CUHK) since 2025. He holds the Li Ka Shing Professor of Medicine title and serves as Associate Dean (Research) and Director of the Li Ka Shing Institute of Health Sciences at CUHK's Faculty of Medicine . His groundbreaking work in non-invasive prenatal testing (NIPT) and cell-free fetal DNA detection has revolutionized prenatal diagnostics and cancer genomics. Research Interests : Dennis Lo's research spans molecular biology, focusing on cell-free DNA analysis in maternal blood plasma for prenatal testing and cancer profiling. He pioneered NIPT using next-generation sequencing (NGS) and DNA methylation differences to detect fetal and tumor mutations. His work also includes SARS virus sequencing during the 2003 outbreak and exploring fetal RNA expression in maternal circulation. Key Awards : Breakthrough Prize in Life Sciences (2021) Royal Medal (2021) Lasker-DeBakey Clinical Medical Research Award (2022) Future Science Prize (2016) Scientific Leadership : Lo co-founded biotech companies Cirina (acquired by GRAIL) and Xcelom to commercialize his discoveries. He serves as Associate Editor of Clinical Chemistry and has held leadership roles in Hong Kong's Technology and Innovation Functional Constituency.

Hao WuView profile

Associate Professor

• Epigenomics
• DNA methylation and demethylation
• Transcriptional control
• +4 more

Hao Wu, PhD is an Associate Professor of Genetics at the University of Pennsylvania's Perelman School of Medicine. He is a Core member of the Penn Epigenetics Institute, Member of the Penn Cardiovascular Institute (CVI), Member of the Penn Institute of Regenerative Medicine (IRM), and Member of the CHOP Center for Mitochondrial and Epigenomic Medicine (CMEM). His educational background includes: B.S. in Biological Sciences and Biotechnology from Tsinghua University (2002) Ph.D. in Epigenetic regulation of neural stem cell differentiation from University of California Los Angeles (2009) Dr. Wu's research focuses on understanding how epigenetic processes regulate gene expression to establish diverse cell types and respond to environmental signals. His lab combines experimental approaches with bioinformatics to study cell-type specification and maturation from mammalian stem cells, particularly in cardiovascular and neural lineages. The Wu lab investigates molecular mechanisms regulating the interaction between environment and epigenome, and how extrinsic signals modify epigenetic marks to influence development or disease. Their long-term goal is to quantitatively analyze and engineer cell-type specific epigenomes to inform therapeutic approaches for human diseases. Analysis of Dr. Wu's recent publications reveals a strong focus on single-cell and spatial multiomic technologies to investigate epigenetic regulation. His work spans cardiovascular biology, neuroscience, and stem cell biology, with emphasis on DNA methylation/demethylation, transcriptional control, and development of novel genomic sequencing methods. Recent publications highlight advances in single-cell epigenomic profiling, time-resolved RNA sequencing, and their application to neural development, cardiac maturation, and disease mechanisms. As a mentor, Dr. Wu oversees a diverse research group including postdoctoral fellows, graduate students, research specialists, and undergraduates. His lab members work on various projects related to epigenomic profiling, epigenome editing, and single-cell technologies. Dr. Wu's research is supported by grants enabling the development of innovative genomic technologies and their application to understand fundamental biological processes. The Wu Lab maintains a collaborative environment focused on developing high-precision single-cell epigenomic profiling methods, novel epigenome editing tools, and time-resolved single-cell RNA sequencing approaches. Current projects investigate neural development, cardiac lineage specification, and the environment-epigenome interaction, bridging fundamental epigenetic mechanisms with translational applications.

Sophia TsokaView profile

Associate Professor

• Computational genome analysis
• Genome data mining
• Network analysis and reconstruction
• +7 more

Sophia Tsoka is a Reader in Bioinformatics at King's College London specializing in computational genome analysis, network reconstruction, and machine learning applications in cancer immunology and microbiome research. She leads the 'Algorithms for Antibodies' project funded by the Royal Society and serves as Co-Investigator on multiple research projects including 'Understanding the significance of patient B cells and expressed antibodies in melanoma' supported by the British Skin Foundation. Dr. Tsoka's research focuses on computational genome analysis, genome data mining, network analysis and reconstruction, metabolic networks, protein interaction networks, and the evolution of genome properties and dynamics. Her work bridges bioinformatics, machine learning, and immunology, with particular emphasis on applying computational approaches to understand antibody mechanisms, tumor microenvironments, and microbiome dynamics. She has developed innovative algorithms for network analysis, classification, and multi-omics data integration that have advanced our understanding of complex biological systems. Her recent publications demonstrate a strong trajectory in applying computational methods to cancer immunology, with multiple high-impact papers in 2025 spanning IgE antibody therapeutics, tumor microenvironment analysis, and machine learning approaches for biomedical data. These works reveal a consistent focus on developing interpretable computational models that can translate complex biological data into clinically relevant insights. Best paper award (2022) Best Paper Award (2020) Dr. Tsoka supervises numerous research projects and has secured significant grant funding from prestigious organizations including the Royal Society and British Skin Foundation. Her collaborative work spans multiple disciplines, connecting computational scientists with immunologists and clinicians to advance cancer therapeutics. She has established herself as a key contributor to the field of computational immunology with over 4,800 citations to her work. Her laboratory focuses on developing and applying advanced computational methods for analyzing complex biological networks, with particular emphasis on cancer immunology applications. The team combines expertise in algorithm development, machine learning, and biological data analysis to address challenging problems in antibody engineering and tumor microenvironment characterization.

Huiru ZhengView profile

Professor

• Bioinformatics
• Healthcare Informatics
• Machine Learning
• +6 more

Professor Huiru (Jane) Zheng is a Professor of Computer Science at the School of Computing, Ulster University. She serves as Theme Leader of Data Analytics and Systems in the AI Research Centre and is a full member of the Computer Science Research Institute. As a Fellow of the UK Higher Education Academy and Senior Member of IEEE, she has established herself as a leading researcher with significant contributions to bioinformatics and healthcare informatics. Her educational background includes: PhD in Bioinformatics (2003) from Ulster University Postgraduate Certificate in Teaching in Higher Education (2005) from Ulster University Professor Zheng's research spans multiple domains of data science with applications in healthcare, agriculture, and environmental monitoring. Her primary interests include integrative data analytics in systems biology, machine learning for healthcare decision support, and assistive technology development. She has particular expertise in applying advanced data mining techniques to complex biological datasets, with a focus on improving healthcare outcomes and supporting independent living through technology. Her extensive publication record demonstrates a clear trend toward interdisciplinary research that bridges computer science with practical applications. Recent work shows increasing focus on real-world implementations of AI in digital health, precision agriculture, and environmental monitoring systems. The breadth of her research interests is evident in publications ranging from gait analysis using smart insoles to methane prediction in dairy farming and wildfire monitoring using UAVs. Professor Zheng has received notable recognition for her contributions: Fellow of the UK Higher Education Academy Senior Member of IEEE As a principal investigator, Professor Zheng has successfully secured substantial research funding from diverse sources including EPSRC, TSB, DEL, NHS, Invest NI, Innovation UK, and the European Commission. Her leadership extends to editorial roles for international journals and organizing major conferences such as the UK Workshop on Computational Intelligence. She has supervised numerous research students through her various projects. Professor Zheng leads several active research initiatives including the AI Research Centre's Data Analytics and Systems theme. Her current projects involve developing digital twin technology for personalized healthcare, AI-assisted systems for post-stroke rehabilitation, methane prediction models for sustainable dairy farming, and age-friendly built environment assessment systems. These projects often involve multidisciplinary collaboration across computer science, healthcare, agriculture, and environmental science domains.

• Virology
• RNA Biology
• MicroRNA Research
• +5 more

Nicolas Julien Fossat serves as an Associate Professor in the Department of Immunology and Microbiology at the Faculty of Health and Medical Sciences, University of Copenhagen. His research spans virology, RNA biology, and developmental biology with a particular focus on viral-host interactions and molecular mechanisms of disease. His research interests primarily focus on RNA biology and virology, with significant contributions to understanding viral RNA modifications, microRNA interactions in viral infections, and the molecular mechanisms of viral replication. His work on Hepatitis C virus RNA capping with flavin adenine dinucleotide represents a major discovery in the field of virology. Additionally, his research extends to developmental biology, particularly in understanding transcription factor networks like TWIST1 in cell differentiation processes. Analysis of his recent publications reveals a strong emphasis on RNA-virus interactions, particularly with flaviviruses including Hepatitis C, yellow fever, and tick-borne encephalitis viruses. His work on SARS-CoV-2 microRNA interactomes during the pandemic demonstrates his ability to pivot research toward emerging health threats. His publications in high-impact journals including Nature, Nature Communications, and Cell Reports highlight the significance of his contributions to the field. Fossat has established productive collaborations with prominent researchers including Bukh, Scheel, and Ramirez, resulting in multiple high-impact publications. His work has received substantial attention, with several papers being highlighted in news outlets and social media platforms, indicating the broader impact of his research.

Andrzej DziembowskiView profile

Professor

• RNA Biology
• Posttranscriptional Regulation
• Gene Expression
• +4 more

Professor Andrzej Dziembowski serves as Head of the Laboratory of RNA Biology - ERA Chairs Group at the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), while maintaining a 25% appointment as Associate Professor at the University of Warsaw's Faculty of Biology. Appointed Professor by the President of Poland in 2014, he leads a multidisciplinary team investigating posttranscriptional regulation of gene expression in metazoans. His laboratory focuses on two primary research areas: Analysis of processive ribonucleases that shape transcriptomes through RNA degradation, with implications for multiple myeloma (where DIS3 mutations are frequent) Analysis of cytoplasmic poly(A) and poly(U) polymerases, particularly the TENT5 family's role in bone formation, immune response, and cancer Professor Dziembowski's recent work demonstrates how cytoplasmic polyadenylation regulates diverse biological processes, from LINE-1 retrotransposition restriction to proper bone development. His team employs transgenic mouse models generated through their CRISPR/Cas9 facility (crisprmice.eu), which has produced over 20 mouse lines in three years. Notable recognition includes: EMBO Membership (2018) Corresponding Member of Polish Academy of Sciences (2020) Multiple Foundation for Polish Science awards Knight's Cross of the Order of Polonia Restituta (2013) He has supervised ten PhD students to completion and currently mentors six doctoral candidates. His laboratory comprises senior researchers, postdoctoral fellows, technicians, and undergraduate students working across multiple research projects including the GRIEG-funded study on cytoplasmic polyadenylation in neuronal translation.

Anton A. KomarView profile

Professor

• Protein Synthesis
• Co-translational Protein Folding
• Translational Control of Gene Expression
• +5 more

Anton A. Komar is a Professor and Director of the Center for Gene Regulation in Health and Disease (GRHD) at Cleveland State University's College of Arts and Sciences. His research focuses on protein synthesis, co-translational protein folding, and translational control of gene expression in eukaryotic cells. He maintains an active laboratory investigating the structure and function of eukaryotic initiation factors and the impact of synonymous mutations on protein function. Dr. Komar's research interests center on understanding how translation initiation works in eukaryotic cells, particularly focusing on eukaryotic initiation factor eIF2A. His work explores how synonymous codon usage along mRNA modulates protein translation kinetics, providing an active mechanism for coordinating the synthesis, maturation and folding of nascent polypeptides. This research has significant implications for understanding human diseases including diabetes and cancer. His recent publications demonstrate consistent research activity in protein translation mechanisms, with a particular focus on how ribosome function shapes protein folding. His work spans from fundamental molecular mechanisms to applications in viral genomics and hemophilia research. Dr. Komar has maintained a strong publication record throughout his career, with significant contributions to understanding the relationship between codon usage and protein folding. As Director of GRHD, Dr. Komar oversees a research center that facilitates collaborative work across disciplines, supporting both basic and translational research in gene regulation. His leadership role indicates his standing within the university's research community. Dr. Komar mentors several graduate students and postdoctoral fellows, maintaining an active laboratory focused on eukaryotic translation mechanisms. His work has contributed significantly to understanding how translational control plays a pivotal role in development, differentiation, cell cycle progression, cell growth, apoptosis, and stress responses.

• Cancer Biology
• Tumor Heterogeneity
• Glioblastoma Research
• +3 more

Michalina Janiszewska is an Assistant Professor at the University of Florida leading the SR-MM-JANISZEWSKA LAB, where her research focuses on intratumor heterogeneity dynamics in aggressive brain tumors. Her work bridges molecular oncology and translational research to uncover mechanisms driving therapy resistance in glioblastoma and other cancers. Her educational background includes a Ph.D. in Life Sciences from the University of Lausanne (2012), a Master's of Science in Medical Biotechnology from the University of Wroclaw (2007), and a Bachelor's of Science in Biotechnology from the University of Wroclaw (2005). Dr. Janiszewska's research centers on how subclonal cancer cell populations interact with tumor microenvironments to drive disease progression. Her lab employs single-cell genomics, spatial transcriptomics, and molecular techniques to investigate RNA-binding proteins (particularly IMP2), epigenetic regulators like HDACs and EZH2, and vascular niche organization in glioblastoma. Key interests include cancer stem cell maintenance, mutation-dependent heterogeneity, and microenvironmental influences on therapeutic response. Analysis of her recent publications reveals a cohesive focus on tumor heterogeneity across multiple dimensions: spatial organization in recurrent glioblastoma, single-cell genomic variations in breast cancer, and epigenetic vulnerabilities in cancer evolution. Her work consistently connects molecular mechanisms to clinical resistance patterns, with strong emphasis on RNA biology and microenvironmental interactions as therapeutic targets. Dr. Janiszewska currently manages three active research grants: Principal Investigator for "Oncofetal protein as a therapeutic target in pediatric brain tumors" (FL DEPT OF HLTH LIVE LIKE BELLA, June 2024) Principal Investigator for "Scott R. MacKenzie Foundation Final Grant application" (UF FOUNDATION via SCOTT R MACKENZIE FOUNDATION, December 2023) Project Manager for "American Cancer Society Institutional Research Grant" (AMERICAN CANCER SOCIETY, January 2022) These projects support her lab's mission to translate heterogeneity research into clinical applications. The SR-MM-JANISZEWSKA LAB specializes in dissecting intratumor heterogeneity in brain tumors through advanced molecular techniques. The lab investigates cancer stem cell regulation, RNA-protein interactions, and spatial tumor architecture to develop strategies targeting therapy-resistant subclones. Current work emphasizes perivascular niches in glioblastoma recurrence and leveraging collateral lethality for precision interventions.

• RNA-Targeted Therapeutics
• Precision Medicine
• Chemoinformatics
• +7 more

Matthew Disney is an Associate Professor of Chemistry at Scripps Research with a distinguished career in RNA-targeted drug discovery. His laboratory has pioneered approaches to design selective therapeutics directly from genome sequence, bridging chemoinformatics and RNA structural biology to develop precision medicines for challenging diseases. Dr. Disney's research interests center on RNA-targeted therapeutics, focusing on developing rational approaches to design small molecules that selectively target disease-causing RNAs. His work spans multiple disease areas including neuromuscular disorders, neurodegenerative diseases (Alzheimer's, ALS), difficult-to-treat cancers (breast, pancreatic, prostate), and infectious diseases. He has developed the proprietary Inforna platform that merges chemoinformatics and RNA structure to identify lead compounds targeting disease-associated RNAs, and has pioneered RIBOTACs (Ribonuclease-Targeting Chimeras) technology for catalytic RNA degradation. His recent publications reveal a strong focus on covalent RNA targeting, transcriptome-wide binding site mapping, and the development of orally bioavailable compounds for neurological disorders. The research demonstrates increasing sophistication in RNA-targeted drug design, with emphasis on selectivity, potency, and clinical translation. ACS 2022 Nobel Laureate Signature Award for Graduate Education in Chemistry Raymond and Beverly Sackler International Prize in Chemistry (2019) NIH Director's Pioneer Award (2015) Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry (2016) Eli Lilly Award in Biological Chemistry (2013) Dr. Disney's research is supported by numerous active grants from NIH, foundations including the Rainwater Charitable Foundation, and industry partners like AstraZeneca and Astellas Pharma. His laboratory trains the next generation of scientists in RNA-targeted drug discovery while advancing multiple therapeutic candidates toward clinical development. Current research includes the Druggable Transcriptome Project, which aims to systematically identify and target disease-relevant RNAs across the human transcriptome.

• Haematopoietic Stem Cell Biology
• Leukemia
• Myeloid Malignancies
• +7 more

Kristian Gurashi is a Postdoctoral Researcher in the Mead Group at the University of Oxford, focusing on Normal and Malignant Haematopoietic Stem Cell Biology . His work integrates multiomic approaches to study myeloid malignancies such as chronic myelomonocytic leukemia (CMML), myelofibrosis, and myelodysplastic syndromes (MDS). Key Research Areas: Haematopoietic Stem Cell Biology Myeloid Malignancies Single-Cell Genomics Organoid Modeling Precision Medicine Immune Suppression Mechanisms His recent publications highlight the application of single-cell sequencing , spatial transcriptomics , and organoid models to dissect clonal evolution, microenvironmental interactions, and therapeutic resistance. Notable trends include studies on TP53 mutations , JAK2 allelic burden , and MDMX expression as prognostic and therapeutic indicators. His work also explores inflammatory signaling and aberrant cell communication in disease progression.

Alisa YurovskyView profile

Lecturer

• Computational Biology
• Computer Science
• Genetics
• +5 more

Alisa Yurovsky is a Lecturer and IDEA Fellow at the Department of Biomedical Informatics at Stony Brook University. Her research focuses on computational biology at the intersection of computer science, genetics, and statistics to advance precision medicine. She earned her PhD in Computer Science from Stony Brook University under Steven Skiena, an M.S. in Computational Biology from EPFL under Bernard Moret, and a B.S. in Computer Science with a Mathematics minor from Carnegie Mellon University. Research Interests: Alisa develops computational algorithms for precision medicine applications, particularly addressing racial disparities in health data. Her current projects include compartment deconvolution in mixed tissue samples, spatial transcriptomics analysis, small-size differential expression studies, and machine learning in biomedical informatics. Publications Trends: Her recent work spans spatial transcriptomics, survival analysis, and machine learning applications in genomics. She has contributed to algorithms for cell-cycle phase detection, ribosomal frameshift identification, and non-negative matrix factorization. Scientific Awards: 2023 IDEA Fellowship 2020 NSF/CRA/CCC Computing Innovation Postdoctoral Fellow 2017 CEWIT Best Poster Award 2016 NSF Graduate Research Fellowship 2010 Prix Annaheim-Mattille for Master’s Thesis 2007 Cadence Design Systems Award Advising and Grants: She mentors undergraduate and high school students through Stony Brook’s VIP Webgen team and Simons Summer Research Program. Her research has received support from NSF and institutional grants.

Mehdi DamaghiView profile

Assistant Professor

• Cancer Evolution
• Tumor Microenvironment
• Metabolic Reprogramming
• +7 more

Mehdi Damaghi, PhD is an Assistant Professor in the Department of Pathology at the Renaissance School of Medicine, Stony Brook University, and a faculty member at the Stony Brook Cancer Center. His research focuses on understanding cancer through ecological-evolutionary principles, with particular emphasis on breast and ovarian cancers. Dr. Damaghi received his BSc in Cell & Molecular Biology-Genetics from Chamran University in Iran (1998-2002), his MSc in Biochemistry from Tarbiat Modares University in Iran (2002-2005), and his PhD in Cell Biology and Genetics from the Max Planck Institute in Dresden, Germany (2008-2012). He completed postdoctoral training at the Moffitt Cancer Center (2012-2017) and served as a Research Scientist (2017-2021) and Instructor (2021) there before joining Stony Brook University. Dr. Damaghi's research applies ecological and evolutionary principles to understand cancer initiation, progression, and metastasis. His lab investigates how tumor cells adapt to variable microenvironments, leading to metabolic reprogramming linked to epigenetics and transcription factors. He studies the interplay between tumor cells and their microenvironment, which drives genotypic heterogeneity and phenotypic plasticity. His work integrates single-cell multi-omics approaches (genome, epigenome, transcriptome, proteome, and metabolome) with pathomics analysis to capture cancer cell heterogeneity in their natural context. An analysis of Dr. Damaghi's recent publications reveals a strong focus on cancer metabolism, particularly how tumor acidosis and hypoxia influence cancer progression and treatment resistance. His work bridges evolutionary biology with cancer research, examining how selective pressures in the tumor microenvironment drive adaptive changes in cancer cells. Key themes include metabolic reprogramming, lysosomal function in acidic environments, and the application of ecological principles to improve cancer treatment strategies, especially for breast and ovarian cancers. NIH/NCI U01CA261841-01 as PI: "Ecology and Evolution of Breast Cancer" (2021-2026) NIH/NCI R01CA249016-01 as Co-PI: "Radiomics and Pathomics to Predict Progress of DCIS Lesion" (2021-2026) Dr. Damaghi actively mentors students and researchers, with openings available for MSc, PhD, MD/PhD, and postdoctoral positions in his lab. His lab, the Damaghi Research Lab, focuses on four main projects: 1) Ecology and Evolution of Breast Carcinogenesis, 2) Metabolic phenotypes in DCIS to stratify disease progression, 3) Co-evolution of tumor and stroma in breast cancer, and 4) Evolution of resistant phenotype to PARPi in ovarian cancer.